Chen IM, Johansen AZ, Dehlendorff C, et al. - Researchers investigated the value of combined detection of serum Interleukin-6 (IL-6), YKL-40, and C-reactive protein (CRP) as a prognosticator for patients with pancreatic cancer (PC) receiving palliative chemotherapy. The BIOPAC biomarker study included 592 patients with unresectable PC from five hospitals in Denmark between 2008 and 2017. The analysis revealed worse survival in association with combined elevations of serum IL-6, YKL-40, and CRP in contrast to an isolated high concentration of a single marker. Patients with advanced-stage disease and patients with poor performance status exhibited higher serum IL-6, YKL-40, and CRP. They noted overall shorter survival in association with higher IL-6 and YKL-40 levels at the time of tumor progression and serum IL-6 measured over time. These findings support the possible significance of assessment of systemic inflammation via measurements of IL-6, YKL-40, and CRP for PC prognostication.